COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:
Working… Menu
Trial record 1 of 3 for:    FIX-HF-5C
Previous Study | Return to List | Next Study

Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System (FIX-HF-5C2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03339310
Recruitment Status : Completed
First Posted : November 13, 2017
Last Update Posted : January 14, 2020
Information provided by (Responsible Party):
Impulse Dynamics

Brief Summary:
This is a multicenter, prospective, single-arm study of the Optimizer Smart System with 2-leads

Condition or disease Intervention/treatment Phase
Heart Failure Congestive Heart Failure Chronic Heart Disease CHF Device: Optimizer Smart System with 2-leads Not Applicable

Detailed Description:
This is a multicenter, prospective, single-arm treatment only confirmatory study of the 2-lead configuration of the Optimizer Smart System.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Optimizer Smart System
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: FIX-HF-5C2: Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%
Actual Study Start Date : October 23, 2017
Actual Primary Completion Date : October 30, 2019
Actual Study Completion Date : October 30, 2019

Arm Intervention/treatment
Experimental: Optimizer Smart System with 2-leads
All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
Device: Optimizer Smart System with 2-leads
The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
Other Name: Optimizer Smart System

Primary Outcome Measures :
  1. Change in exercise tolerance quantified by peak VO2 measured on cardiopulmonary exercise stress testing (CPX). [ Time Frame: 24 weeks ]
    Device efficacy will be assessed as change in exercise tolerance quantified by peak VO2 measured on cardiopulmonary exercise stress testing (CPX). Subjects on device under FIX-HF-5C2 protocol will be compared to subjects on control under FIX-HF-5C protocol with respect to peak V02 mean change at 24-weeks from baseline.

  2. Optimizer-device and -procedure related complication rate [ Time Frame: 24 weeks ]
    Subjects experiencing an Optimizer device- or procedure-related complication through the 24-week study period, as determined by an independent events committee.

Secondary Outcome Measures :
  1. Total CCM delivery comparing 2 and 3-lead device configurations [ Time Frame: 24 weeks ]
    A comparison will be made between the Optimizer per-protocol groups in the FIX-HF-5C (3-lead) and FIX-HF-5C2 (2-lead) device configurations to show there is no difference between the amount of CCM therapy provided by the two device configurations. Total CCM delivery (effective hours delivered) will be evaluated at the end of 24 weeks following the Optimizer implantation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects who are 18 years of age or older
  • Subject is male or a non-pregnant female
  • Subjects who have a baseline ejection fraction greater than or equal to 25% and less than or equal to 45% by echocardiography determined by the echocardiography core laboratory.
  • Subjects who have been treated for heart failure for at least 90 days (including treatment with a β-blocker for at least 90 days unless the subject is intolerant) and are in New York Heart Association functional Class III and IV at the time of enrollment.
  • Subjects receiving appropriate, stable medical therapy during the 30 days prior to enrollment for treatment of heart failure according to guideline recommendations. For patients with EF≤35%, this regimen shall consist of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor blocker and β-blocker. Angiotensin receptor -neprilysin inhibitor (ARNI) may be substituted for ACE inhibitors or ARBs and Ivabradine may also be considered in subjects with a heart rate >70bpm. Stable is defined as no more than a 100% increase or 50% decrease in dose.
  • Subjects who, in the opinion of the Principal Investigator (based on the current guidelines for clinical practice), have a clinical indication for an implanted cardiac defibrillator (ICD, e.g., EF≤35%) and/or pacemaker, must have an existing device unless the patient refuses to undergo the implantation of such device for personal reasons.
  • Subjects who are willing and able to return for all follow-up visits.

Exclusion Criteria:

  • Subjects whose baseline peak VO2 is <9 or >20 ml O2/min/kg. The qualifying CPX test must be deemed adequate.
  • Subjects who have a potentially correctible cause of heart failure, such as valvular heart disease or congenital heart disease.
  • Subjects who have clinically significant angina pectoris, consisting of angina during daily life (i.e., Canadian Cardiovascular Society Angina score of II or more), an episode of unstable angina within 30 days before enrollment, or angina and/or ECG changes during exercise testing performed during baseline evaluation.
  • Subjects hospitalized for heart failure requiring acute treatment with intravenous loop diuretics, IV inotropes or hemofiltration within 30 days before enrollment and baseline testing or subjects receiving any form of positive inotropic support within 30 days before enrollment, including continuous IV inotrope therapy.
  • Subjects having a PR interval greater than 375ms.
  • Subjects whose exercise tolerance is limited by a condition other than heart failure (e.g., angina, COPD, peripheral vascular disease, orthopedic or rheumatologic conditions) or who are unable to perform baseline stress testing.
  • Subjects who are scheduled for a CABG or a PTCA procedure, or who have undergone a CABG procedure within 90 days or a PTCA procedure within 30 days of enrollment.
  • Subjects who have a biventricular pacing system, an accepted indication for such a device, or a QRS width of 130ms or greater.
  • Subjects who have had a myocardial infarction within 90 days of enrollment.
  • Subjects who have mechanical tricuspid valve.
  • Subjects who have a prior heart transplant.
  • Subjects on dialysis.
  • Subjects who are participating in another experimental protocol.
  • Subjects who are unable to provide informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03339310

Layout table for location information
United States, Arizona
Chan Heart Rhythm Institute
Mesa, Arizona, United States, 85206
Southwest Cardiology Associates
Mesa, Arizona, United States, 85206
Cardiovascular Consultants
Phoenix, Arizona, United States, 85032
Arizona Arrhythmia Consultants
Scottsdale, Arizona, United States, 85251
Pima Heart Physicians, PC
Tucson, Arizona, United States, 85712
United States, Illinois
Baptist Health Systems
Lexington, Illinois, United States, 40503
United States, Louisiana
Ochsner Clinic Foundation
New Orleans, Louisiana, United States, 70121
United States, Texas
Dallas VA Hospital
Dallas, Texas, United States, 75216
CHRISTUS Trinity Mother Frances
Tyler, Texas, United States, 75701
University Hospital gGmbH Bergmannsheil
Bochum, Germany, 44789
Sponsors and Collaborators
Impulse Dynamics
Layout table for investigator information
Study Director: David D. Gutterman, MD Medical College of Wisconsin
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Impulse Dynamics Identifier: NCT03339310    
Other Study ID Numbers: CP OPT2017-005
FIX-HF-5C2 ( Other Identifier: Impulse Dynamics )
First Posted: November 13, 2017    Key Record Dates
Last Update Posted: January 14, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Impulse Dynamics:
CCM Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases